2008
Workshop on HIV Infection and Aging: What Is Known and Future Research Directions
High K, Effros R, Fletcher C, Gebo K, Halter J, Hazzard W, Horne F, Huebner R, Janoff E, Justice A, Kuritzkes D, Nayfield S, Plaeger S, Schmader K, Ashworth J, Campanelli C, Clayton C, Rada B, Woolard N, High K. Workshop on HIV Infection and Aging: What Is Known and Future Research Directions. Clinical Infectious Diseases 2008, 47: 542-553. PMID: 18627268, PMCID: PMC3130308, DOI: 10.1086/590150.Peer-Reviewed Original ResearchConceptsHIV infectionHuman immunodeficiency virus (HIV) infectionInfectious diseasesImmunodeficiency virus infectionInfectious Diseases SocietyActive antiretroviral treatmentNational InstituteDiseases SocietyAntiretroviral treatmentImmunodeficiency syndromeAdvanced ageChronic diseasesVirus infectionDrug toxicityInfectionSpecialty ProfessorsLife expectancyDiseaseComorbiditiesMedical AssociationHigh-priority topicsTreatmentAssociationAging processPriority topics
2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. The Lancet 2003, 362: 679-686. PMID: 12957089, DOI: 10.1016/s0140-6736(03)14229-8.Peer-Reviewed Original ResearchConceptsCells/microLHIV-1 RNACopies/mLCD4 countHazard ratioHIV-1Current CD4 cell countPotent antiretroviral therapyCD4 cell countTreatment-naive patientsYears of followActive antiretroviral treatmentHigh-risk stratumSubsequent disease progressionLow-risk stratumProbability of progressionBaseline CD4Antiretroviral therapyCohort studyAntiretroviral treatmentMonth 6Viral loadClinical progressionPrognostic importanceProspective study